Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Noxopharm Ltd. ( (AU:NOX) ) has issued an announcement.
Noxopharm Limited has announced significant progress in the recruitment phase of its HERACLES clinical trial, which is testing SOF-SKN™, a first-in-class drug candidate for autoimmune diseases. The trial aims to assess the safety of SOF-SKN in treating cutaneous lupus erythematosus and potentially other autoimmune-related skin conditions. The company has completed the manufacturing of SOF-SKN and is finalizing quality control measures, with the trial benefiting from Australian expertise and federal R&D tax incentives. This advancement underscores Noxopharm’s strategic focus on leveraging its Sofra™ technology for broader applications in autoimmune and inflammatory diseases.
More about Noxopharm Ltd.
Noxopharm Limited is a clinical-stage Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company leverages its proprietary technology platforms, Sofra™ and Chroma™, to enhance mRNA medicines and develop drugs targeting inflammation, autoimmunity, and oncology.
Average Trading Volume: 105,819
Technical Sentiment Signal: Sell
Current Market Cap: A$17.53M
For a thorough assessment of NOX stock, go to TipRanks’ Stock Analysis page.